News
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
— Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumors
— Trial overview presented at ESMO Congress 2023 (Madrid, Spain)
— Dose levels 1 and 2 successfully completed
ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia. The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
– Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its lead compound IOS-1002 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in an ongoing Phase 1a/b clinical trial for the treatment of patients with advanced solid tumors.
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression
– First data readout expected in Q1/ 2024 with study completion planned for September 2024
Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the safety, tolerability, and clinical outcomes of MyopiaX® in pediatric participants with myopia. Read more…
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
— Submission represents an important step towards establishing the Cellbox Live Shipment Technology as a new standard for warm chain logistic in the cell therapy sector
— Cellbox customers can now reference the DMF, simplifying and accelerating their regulatory approval process for cell therapy production processes involving the Cellbox Technology
Hamburg, Germany, September 25, 2023 – Cellbox Solutions GmbH, a leading provider of warm chain logistics solutions for the research, development and shipment of cell-based therapies and cellular diagnostics, today announced that is has successfully submitted a Device Master File (DMF) for its Cellbox Live Shipment Technology to the U.S. Food and Drug Administration’s (FDA). Read more…